Skip to content

Dopaminergic, Functional, Structural, and Cognitive Disturbances in First-episode Schizophrenia

Effects of Classical and Atypical Antipsychotics on Dopamine Receptor Binding of 123I-epidepride, Cognition, Startle Response and Extrapyramidal Side-effects in Drug-naive First-episode Schizophrenic Patients

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00206960
Enrollment
56
Registered
2005-09-21
Start date
1998-01-31
Completion date
2010-09-30
Last updated
2011-09-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia

Keywords

drug-naive, epidepride, single tomography, D2 receptor, information processing, PPI, antipsychotic treatment, MRI, fMRI, cognitive disturbances

Brief summary

We wanted to compare dopamine D2 receptor activity, brain structure, brain function, sensory gating and cognition in neuroleptic-naive schizophrenic patients and matched healthy controls. Additionally, we wanted to examine the effects of 3 months of treatment with either low doses of a typical or an atypical antipsychotic compound on the same functions. The hypotheses were that schizophrenic patients suffered from disturbances in brain function and structure, information processing, and extrastriatal D2 receptor activity, and that these disturbances would be related to each other and to psychopathology. Additionally, we expected the atypical compound to have an effect on some of the disturbances in information processing, and that the atypical compound - in contrast to the typical drug - would show extrastriatal over striatal selectivity.

Detailed description

31 neuroleptic-naive schizophrenic patients and 25 matched controls were recruited from the greater Copenhagen area. The patients were randomized to treatment with either low doses of the typical antipsychotic compound, zuclopenthixol, or the atypical drug, risperidone. Patients and controls were examined at base-line and patients were re-examined after 3 months of treatment.The study has resulted in two finish Ph.D. theses (Torben Mackeprang and Birgitte Fagerlund). The data has in part been published in: Mackeprang T, Tjelle Kristiansen K, Glenthoj B. Prepulse inhibition of the startle response in drug-naïve, first-episode schizophrenic patients before and after 3 months of treatment with a typical or an atypical antipsychotic drug. Biological Psychiatry 2002; 52(9): 863-873. and Fagerlund B, Mackeprang T, Gade A, Hemmingsen R, Glenthoj BY. Effects of Low-Dose Risperidone and Low-Dose Zuclopenthixol on Cognitive Functions in First-Episode Drug-Naïve Schizophrenic Patients. CNS Spectr. 2004; 9: 364-74. and Glenthoj BY, Mackeprang T, Svarer C, Rasmussen H, Pinborg L, Friberg L, Baaré W, Hemmingsen R, Videbæk C. Frontal dopamine D2/3 receptor binding in drug-naïve first-episode schizophrenic patients correlates with positive psychotic symptoms and gender. Biological Psychiatry 2006; in press. Mar 30; \[Epub ahead of print\]. PMID: 16784819 \[PubMed - as supplied by publisher\]. We are at present conducting a five-year follow-up study of the same cohort of patients and controls and plan a ten-year follow-up as well. The follow-up studies focus on brain structure (MRI), brain function, information processing, and psychopathology. We will correlate changes in structure and function to treatment, but no interventions (pharmacological or otherwise) are planned.

Interventions

Patients will be administered zuclopenthixol orally in doses between 4 -24 mg/day, depending on an effective reduction of symptoms

DRUGrisperidone

Patients will be administered risperidone orally in doses between 1-6 mg/day, depending on an effective reduction of symptoms

Sponsors

University of Copenhagen
CollaboratorOTHER
Glostrup University Hospital, Copenhagen
CollaboratorOTHER
Rigshospitalet, Denmark
CollaboratorOTHER
Hvidovre University Hospital
CollaboratorOTHER
The Danish Medical Research Council
CollaboratorOTHER
Copenhagen Hospital Corporation
CollaboratorOTHER
Janssen-Cilag Ltd.
CollaboratorINDUSTRY
The Novo Nordic Foundation
CollaboratorOTHER
Birte Glenthoj
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
FACTORIAL
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 45 Years
Healthy volunteers
Yes

Inclusion criteria

* For patients: Clinical diagnosis of schizophrenia. * The controls were matched to the patients.

Exclusion criteria

* Patients: Previous antipsychotic treatment, patients who were compulsorily hospitalised or deemed in acute need of medication, mental retardation * Controls: psychiatric diagnosis, psychiatric diagnosis in first-degree relatives, drug abuse, mental retardation

Design outcomes

Primary

MeasureTime frame
Cognitionprospective
All examinations are done at baseline (patients and controls). In the patient group, they are repeated after 3 months of treatmentprospective
PANSSprospective
SANSprospective
SAPSprospective
MRIprospective
fMRIprospective
startle responseprospective
PrePulse Inhibition of the startle response (PPI)prospective

Secondary

MeasureTime frame
The cognitive test battery comprised tests from the Cambridge Neuropsychological Test Automated Battery (CANTAB) as well as paper-and-pencil cognitive tests.prospective

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026